Fiter J, Nolla J M, Valverde J, Roig Escofet D
Servicio de Reumatología, Hospital Prínceps d'Espanya, Ciutat Sanitària, L'Hospitalet de Llobregat, Barcelona.
Rev Clin Esp. 1995 Jun;195(6):390-2.
Amyloidosis secondary to rheumatoid arthritis is a complication with a poor prognosis and as yet an undefined medical therapy. In the last decades the use of different cytostatics has been advocated to avoid renal function deterioration. The clinical characteristics and course in eight patients with amyloidosis secondary to rheumatoid arthritis are here reported after therapy with low dosage methotrexate. In twelve patients who followed a 12-month therapy a clinical improvement was observed, with a marked decrease in proteinuria; in one of them proteinuria disappeared. These results suggest that methotrexate at low doses might be an alternative in the early treatment of amyloidosis secondary to rheumatoid arthritis in patients with preserved renal function.
类风湿关节炎继发的淀粉样变性是一种预后不良且尚无明确医学治疗方法的并发症。在过去几十年中,人们主张使用不同的细胞抑制剂来避免肾功能恶化。本文报告了8例类风湿关节炎继发淀粉样变性患者在接受低剂量甲氨蝶呤治疗后的临床特征和病程。在12例接受了12个月治疗的患者中,观察到临床症状改善,蛋白尿显著减少;其中1例患者蛋白尿消失。这些结果表明,低剂量甲氨蝶呤可能是肾功能尚好的类风湿关节炎继发淀粉样变性患者早期治疗的一种选择。